SCHEMBL5100708

SCHEMBL5100708

NC(=O)Cc1cnc2[nH]ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.54
CDK8 P49336 10/20 0.51
CDK7 P50613 2/20 0.51
CCNT1 O60563 1/20 0.51
CCND1 P24385 1/20 0.51
CCNC P24863 1/20 0.51
CDK9 P50750 1/20 0.51
CCNH P51946 1/20 0.51
MNAT1 P51948 1/20 0.51
CDK6 Q00534 1/20 0.51
KDR P35968 3/20 0.50
FGFR1 P11362 1/20 0.50
ABL1 P00519 1/20 0.46
MAP4K4 O95819 2/20 0.45
CHEK2 O96017 2/20 0.45
CDK1 P06493 2/20 0.45
FES P07332 2/20 0.45
ROS1 P08922 2/20 0.45
FER P16591 2/20 0.45
FLT4 P35916 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1873717 0.84 KDR (0.53) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL14638748 0.82 KDR (0.56) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL1873713 0.79 KDR (0.48) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL3348784 0.78 CDK8 (0.63) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL1869919 0.78 CDK8 (0.63) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL27033549 0.77 KDR (0.50) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL299515 0.77 KDR (0.56) RIPK1CDK8CDK7CCNT1CCND1
Hydrochloric Acid SCHEMBL7214988 0.77 CDK8 (0.61) RIPK1CDK8CDK7CCNT1CCND1
Hydrochloric Acid SCHEMBL16246682 0.77 CDK8 (0.61) RIPK1CDK8CDK7CCNT1CCND1
SCHEMBL29590039 0.76 KDR (0.51) RIPK1CDK8CDK7CCNT1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 US disclosed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K20, MAP3K6, MAP3K1 RIPK1 494/4885CDK8 30/4885CDK7 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.